Erlocip 150mg

Erlotinib is used for the treatment of locally-advanced and metastatic form of non-small cell carcinoma after the failure of chemotherapy and locally advanced inoperable or metastatic pancreatic cancer as a first-line therapy in combination with Gemcitabine. Currently developed test to access the express target of Erlotinib EGFR in the biopsy must increase the effectiveness of treatment with Erlotinib within personalized therapy. As with Gefitinib, the problem of Erlotinib treatment is the fact that cancer cells acquire resistance to the treatment with EGFR inhibitors after 8-12 months of treatment.

Erlocip 150 mg is an anti-cancer drug that acts by blocking the epidermal growth factor receptor, which in turn inhibits the growth of cancer cells. This drug is used as a first-line treatment of metastatic non-small cell lung cancer and pancreatic cancer. In case of pancreatic cancer, patients are prescribed another anti-cancer agent – Gemcitabine. The main component of this drug belongs to the group of kinase inhibitors.

Contraindications

Erlocip 150 mg can’t be used for the treatment of children, pregnant and breastfeeding women, patients intolerant to any component of this drug and people suffering from severe kidney/liver dysfunction. Some diseases and conditions require expert decision on the safety of use of Erlocip 150 mg in certain patient.

Drug incompatibility can occur. Therefore, your doctor must be aware of all the drugs you’re taking.

Way of use of Erlocip 150 mg

The doctor will define the dose, frequency of use and duration of treatment, depending on the type and location of the tumor, patient’s general condition and the results of previous treatment. The entire daily dose must be taken at once (on an empty stomach or 2 hours after the meal). Take the drug every day, preferably at the same time.

The treatment with Erlocip 150 mg must be conducted under the medical supervision with periodical surveys, aimed at detecting the side effects and defining the results of treatment.

Effectiveness of Erlocip 150 mg was confirmed during the clinical trials, which showed that the use of this drug reliably increases the life expectancy, improves the patient’s condition and inhibits the growth and metastatic spreading of tumor.